Adults are three times as likely to have a heart attack or stroke after a COVID-19 infection than when they are healthy. The risks are even greater for the flu.
Bleeding events remain a serious complication after TAVR. By identifying high-risk patients early and planning ahead, however, care teams can keep them to a minimum.
Pfizer was all set to acquire New York City-based Metsera for $4.9 billion, but Novo Nordisk stepped in with an unexpected counteroffer of $6.5 billion. Both companies hope to add Metsera's drugs to their GLP-1 portfolios.
B. Hadley Wilson, MD, talked to Cardiovascular Business about several standout late-breaking clinical trials presented at TCT 2025. Topics of those trials included drug-coated balloons, TAVR valve durability, pulmonary embolism treatments and much more.
Paradise Ultrasound image courtesy of Recor Medical.
New data on the RDN systems from Recor Medical and Medtronic confirmed that this relatively new technology brings long-term relief to patients with uncontrolled hypertension.
The patient's Trifecta GT heart valve had to be replaced after just six years, an experience he says resulted in "permanent injuries." Abbott pulled the devices off the U.S. market in 2023 due to a known risk of structural valve deterioration.
The Evoque TTVR system. Image courtesy of Edwards Lifesciences.
Researchers tracked data from more than 1,000 real-world patients, focusing on 30-day safety and efficacy outcomes. The group shared its findings at TCT 2025 in San Francisco.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
